Tumor mutational burden, toxicity, and response of immune checkpoint inhibitors targeting PD (L) 1, CTLA-4, and combination: a meta-regression analysis
A Osipov, SJ Lim, A Popovic, NS Azad, DA Laheru… - Clinical Cancer …, 2020 - AACR
Purpose: Tumor mutational burden (TMB) has emerged as a potential predictive biomarker
for clinical response to ICI therapy, but whether TMB also predicts toxicity remains unknown. …
for clinical response to ICI therapy, but whether TMB also predicts toxicity remains unknown. …
[HTML][HTML] Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape
A Osipov, MT Saung, L Zheng, AG Murphy - Journal for immunotherapy of …, 2019 - Springer
Immunotherapy has led to a paradigm shift in the treatment of many advanced malignancies.
Despite the success in treatment of tumors like non-small cell lung cancer (NSCLC) and …
Despite the success in treatment of tumors like non-small cell lung cancer (NSCLC) and …
[HTML][HTML] Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses
…, H Jing, K Fujiwara, H Hu, A Osipov… - Journal of Hematology & …, 2022 - Springer
Background Immunotherapy has demonstrated a limited clinical efficacy in approximately 5%
of cholangiocarcinoma. The main challenges for an effective immunotherapy response in …
of cholangiocarcinoma. The main challenges for an effective immunotherapy response in …
[PDF][PDF] Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy
Successful pancreatic ductal adenocarcinoma (PDAC) immunotherapy necessitates
optimization and maintenance of activated effector T cells (Teff). We prospectively collected and …
optimization and maintenance of activated effector T cells (Teff). We prospectively collected and …
[HTML][HTML] A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer
…, SL Shiao, N Nissen, M Tighiouart, S Kim, A Osipov… - …, 2019 - thelancet.com
Background Locally advanced pancreatic cancer (LAPC) has a dismal prognosis with
current treatment modalities and one-third of patients die from local progression of disease. …
current treatment modalities and one-third of patients die from local progression of disease. …
[HTML][HTML] Advances in pancreatic ductal adenocarcinoma treatment
…, S Thomassian, J Gong, A Hendifar, A Osipov - Cancers, 2021 - mdpi.com
Simple Summary Pancreatic cancer remains one of the most challenging malignancies to
treat with standard approaches. Emerging treatment approaches incorporating innovative …
treat with standard approaches. Emerging treatment approaches incorporating innovative …
From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy
A Osipov, A Murphy, L Zheng - Advances in cancer research, 2019 - Elsevier
Cancer is a worldwide medical problem with significant repercussions on individual patients
and societies as a whole. In order to alter the outcomes of this deadly disease the treatment …
and societies as a whole. In order to alter the outcomes of this deadly disease the treatment …
[HTML][HTML] Identifying prognostic intratumor heterogeneity using pre-and post-radiotherapy 18F-FDG PET images for pancreatic cancer patients
Background To stratify risks of pancreatic adenocarcinoma (PA) patients using pre-and post-radiotherapy
(RT) PET/CT images, and to assess the prognostic value of texture variations …
(RT) PET/CT images, and to assess the prognostic value of texture variations …
[HTML][HTML] Review of systemic therapies for locally advanced and metastatic rectal cancer
P Yaffee, A Osipov, C Tan, R Tuli… - Journal of …, 2015 - ncbi.nlm.nih.gov
Rectal cancer, along with colon cancer, is the second leading cause of cancer-related deaths
in the US Up to a quarter of patients have metastatic disease at diagnosis and 40% will …
in the US Up to a quarter of patients have metastatic disease at diagnosis and 40% will …
A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer
…, JM Nauroth, C Rodriguez, A Osipov… - Cancer …, 2020 - Wiley Online Library
Background Mismatch repair proficient (MMRp) colorectal cancer (CRC) has been refractory
to single‐agent programmed cell death protein 1 (PD1) inhibitor therapy. Colon GVAX is an …
to single‐agent programmed cell death protein 1 (PD1) inhibitor therapy. Colon GVAX is an …